login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Similar results for laser ablation and surgery at two years


Tuesday, 11 Aug 2009 15:10
Lars Rasmussen
Lars Rasmussen


A study conducted in Denmark has suggested that medium term efficacy and safety of endovascular laser ablation and stripping of the great saphenous veins present similar results. Lars Rasmussen, Danish Vein Centres and Surgical Clinic Roskilde, presented the two-year data at the European Venous Forum.


The objective of the study was to compare laser ablation with stripping (HL/S) with regards to safety and efficacy, quality of life and economy. The inclusion criteria was age 18–80 years, informed consent, varicose veins and great saphenous veins incompetence as defined by duplex, CEAP clinical classification C2–3, previous high ligation and local treatment accepted if great saphenous vein was preserved in its entire length from groin to knee. Bilateral treatment was permitted, provided both limbs were receiving the same treatment during the same operation.


Patients (121) with great saphenous vein insufficiency were randomised using sealed envelopes. Diagnostic was performed with duplex scan. The treatment consisted of high ligation and pin stripping (n=59, 68 legs) or endovascular laser 980 nm, Biolitec (n=62, 69 legs). Division of all saphenous tributaries was done beyond their secondary branches. The procedure included tumescent local anaesthesia, with lidocaine and adrenaline, 0.1%, and compression and absorbant bandage 48 hours, grade 1 stockings for two weeks. Follow-up was conducted at two weeks, four weeks, three, six, 12, and months for safety, efficacy, pain score (1–10 days), time off work and normal activity, economy, VCSS, AVVSS, SF-36 (quality of life), recurrence rate and -pattern. Follow-up at 36 months is also planned.


Two HL/S procedures failed while three great saphenous veins recanalised in the endovascular laser ablation group. The groups experienced similar improvement in quality of life scores and VCSS score. Complications were rare and minor. Postoperative morbidity, improvements in quality of life, venous clinical severity score and costs were similar in the two groups. Twenty-three (33%) and 18 (26%) of the stripping and endovascular laser ablation group respectively developed new varicose veins, a non-significant difference. The distribution of the recurrent varicose veins was not different between the groups; new incompetent femoral perforations being the most frequent finding at follow-up. A total of 11% were re-operated within two years.


The study concluded that expect for slightly increased postoperative pain and bruising in the HL/S group, no differences were found between the two treatment modalities. The treatments were equally safe and efficient in eliminating great saphenous veins reflux, alleviate symptons and signs of varicosities and improve quality of life. The recurrence rate was disappointingly high in both groups, as seen in other studies. Longer term outcomes, particularly with respect to recurrence rates must be investigated in future studies.




Add New Comment

Most popular


Incraft low-profile endograft launched in Europe and Canada
Wednesday, 10 Sep 2014
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from ... Incraft low-profile endograft launched in Europe and Canada

First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

Features


Not all drug-eluting balloons are equal
Wednesday, 15 Oct 2014
Thomas Zeller, Bad Krozingen, Germany, analyses the results of two recent randomised controlled trials comparing drug-eluting balloons to angioplasty alone in femoropopliteal lesions. Not all drug-eluting balloons are equal

Renal stenting may benefit patients excluded from randomised trials, says expert consensus
Wednesday, 15 Oct 2014
Sahil A Parikh, Case Western Reserve University School of Medicine, Cleveland, USA, speaks to Vascular News about the Society for Cardiovascular Angiography and Interventions expert consensus on ... Renal stenting may benefit patients excluded from randomised trials, says expert consensus

Profiles


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions